Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

Carsten Denkert,Chiara Lambertini,Peter A. Fasching,Katherine L. Pogue-Geile,Max S. Mano,Michael Untch,Norman Wolmark,Chiung-Sheng Huang,Sibylle Loibl,Eleftherios P. Mamounas,Gunter von Minckwitz,Charles E. Geyer,Thomas Boulet,Chunyan Song,Gail Lewis Phillips,Malgorzata Nowicka,Sanne de Haas,Mark Basik

Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

2020

Carsten Denkert
Chiara Lambertini
Peter A. Fasching
Katherine L. Pogue-Geile
Max S. Mano
Michael Untch
Norman Wolmark
Chiung-Sheng Huang
Sibylle Loibl
Eleftherios P. Mamounas
Gunter von Minckwitz
Charles E. Geyer
Thomas Boulet
Chunyan Song
Gail Lewis Phillips
Malgorzata Nowicka
Sanne de Haas
Mark Basik

502Background: The phase 3 KATHERINE study (NCT01772472) compared adjuvant T-DM1 versus H in patients with residual invasive breast cancer after neoadjuvant chemotherapy plus HER2-targeted therapy....

Keywords:

Adjuvant
Trastuzumab
Oncology
in patient
Internal medicine
Trastuzumab emtansine
Biomarker (medicine)
Neoadjuvant therapy
Chemotherapy
Breast cancer
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations